CORE--OPTICS AND PHOTODYNAMIC THERAPY DOSIMETRY

核心--光学和光动力治疗剂量测定

• 批准号: 6300404
• 负责人: WILLIAM R POTTER
• 金额: $ 21.92万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-02-01 至 2001-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6300404
• 关键词: biomedical facility; disease /disorder model; dosage; human subject; laboratory mouse; neoplasm /cancer pharmacology; neoplasm /cancer photoradiation therapy; nonvisual photosensitivity; optics; pharmacokinetics; photosensitizing agents; radiation dosage

The overall aim of Core B, the Optics and PDT Dosimetry Core, is to provide support for the light delivery for PDT both in the clinic and in the laboratory. This include the setup for the light delivery devices (lasers, fibers, beam splinters) for both clinical and laboratory photodynamic therapy. PDT in both the laboratory and clinic requires proper dosimetry. The Core provides equipment and personnel to support the research of the projects and works to maximize the yield of useful information. To perform this function it is necessity to understand the dosimetry of PDT. This leads an effort in modeling. The limited understanding of dosimetry as dependent on the light and a drug has been expanded through study of the QSAR data on the pyropheophorbide hexyl ether series to include a sensitive target for PDT. We intend to continue to study the dosimetry of PDT in an attempt to support and provide a testable model framework in which to understand the results of the other projects in the overall study of structure activity relationships. Core personnel will perform laser maintenance, calibration and dosimetric measurements required by the clinical and laboratory research activities of the projects. The specific aims of Core B are: i. Technical support for clinical and scientific lasers; ii. Measurement of photobleaching during therapy; iii. Measurement of the total attenuation of tumor and normal tissue in patients undergoing PDT for the treatment of skin tumors; iv. Study of the pharmacokinetics of pyropheophorbide hexyl ether and subsequent series and ALA; v. PS distributions in frozen sections of tumors and normal tissues; vi. Refining the analytic framework of PDT targeting and dosimetry.

B核心是光学和PDT剂量学核心，其总体目标是 为光动力疗法的临床和临床应用提供支持 实验室。这包括光传输设备的设置 (激光、光纤、分束器)，用于临床和实验室 光动力疗法。 无论在实验室还是临床，光动力疗法都需要适当的剂量学测量。《核心》 为项目研究提供设备和人员支持 并致力于最大限度地产生有用信息。要执行此操作，请执行 功能：了解光动力疗法的剂量学知识是必要的。这导致了一个 在造型上的努力。对剂量学的有限理解依赖于 通过对QSAR数据的研究，扩大了光和药物的范围 焦脱镁叶绿酸已基醚系列包括敏感靶标 光动力疗法。我们打算继续研究光动力疗法的剂量学，以尝试 支持并提供可测试的模型框架，以便在其中理解 其他项目在结构活动总体研究中的结果 两性关系。核心人员将执行激光维护、校准 以及临床和实验室所要求的剂量测量 项目的研究活动。 核心B的具体目标是： 为临床和科学激光提供技术支持； 二、治疗过程中光漂白的测量； 三、肿瘤和正常组织总衰减率的测量 在接受PDT治疗皮肤肿瘤的患者中； 四、焦脱镁叶绿酸己基醚和丙二醛的药代动力学研究 后续系列和ALA； V.PS在肿瘤冰冻切片和正常组织中的分布； 六、细化光动力治疗靶向和剂量学的分析框架。